Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other equities research analysts also recently issued reports about the company. Bank of America reaffirmed a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Catalent in a research report on Wednesday, September 20th. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. First Analysis initiated coverage on Catalent in a research report on Friday, January 5th. They issued an “equal weight” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Catalent has an average rating of “Buy” and a consensus price target of $44.44.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s revenue was up 23.0% compared to the same quarter last year. During the same period last year, the business posted $0.16 earnings per share. analysts forecast that Catalent will post 1.47 earnings per share for the current fiscal year.
In other news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in CTLT. Neuberger Berman Group LLC grew its position in Catalent by 27.1% during the second quarter. Neuberger Berman Group LLC now owns 12,989 shares of the company’s stock worth $456,000 after buying an additional 2,773 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Catalent during the second quarter worth about $235,000. Wells Fargo & Company MN grew its position in Catalent by 42.4% during the second quarter. Wells Fargo & Company MN now owns 677,807 shares of the company’s stock worth $23,790,000 after buying an additional 201,909 shares in the last quarter. Alliancebernstein L.P. grew its position in Catalent by 24.4% during the second quarter. Alliancebernstein L.P. now owns 275,664 shares of the company’s stock worth $9,676,000 after buying an additional 53,990 shares in the last quarter. Finally, Riverhead Capital Management LLC grew its position in Catalent by 83.9% during the second quarter. Riverhead Capital Management LLC now owns 7,354 shares of the company’s stock worth $258,000 after buying an additional 3,354 shares in the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.